search
Back to results

Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells

Primary Purpose

MDS, Anemia, Aplastic, Inborn Errors of Metabolism

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
ALDHbr Umbilical Cord Blood Cells
Sponsored by
Joanne Kurtzberg, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for MDS focused on measuring ALDHbr, Umbilical Cord Blood, Transplantation, Hematological malignancy, MDS, severe aplastic anemia, inborn error of metabolism, congenital marrow failure or congenital immunodeficiency syndrome, Hurler's Disease, Tay Sach's, PMD, Hunter's Syndrome, Krabbe, MLD, ALD, ALL, AML

Eligibility Criteria

undefined - 55 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

-Hematologic Malignancy: High risk ALL in first complete remission ALL or ANLL in second or subsequent remission ANLL in relapse MDS CML in any chronic phase or accelerated phase Severe aplastic anemia refractory to medical therapy The subject is negative for CNS disease at time of enrollment.

  • Inborn errors of metabolism Hurler Syndrome (MPS I) Hurler-Scheie Syndrome Hunter Syndrome (MPS II) Sanfilippo Syndrome (MPS III) Morquio Syndrome (MPS IV) Maroteaux-Lamy Syndrome (MPS VI) Krabbe Disease (Globoid Leukodystrophy) Metachromatic Leukodystrophy (MLD) Adrenoleukodystrophy(ALD and AMN) Sandhoff Disease Tay Sachs Disease The subject does NOT have uncontrolled seizures, apnea, evidence of aspiration pneumonia or evidence of brain stem involvement on MRI scans
  • Congenital marrow failure Amegakaryocytic thrombocytopenia TAR Kostmann's Syndrome Schwachman-Diamond Syndrome Blackfan-Diamond Anemia
  • Congenital immunodeficiency syndromes requiring myeloablative therapy Wiscott Aldrich Syndrome LAD CGD FEL/HLH CVID/CID
  • SUBJECT'S DONOR Subject does NOT have a 6/6 or 5/6 antigen matched related bone marrow donor. Suitably matched cord blood unit with adequate cell dose is available. Unit must be in a dual compartment bag.

PERFORMANCE STATUS and ORGAN FUNCTION

  • <55 years of age at time of enrollment.
  • Lansky score between 60% and 100%, or a Karnofsky score between 50% and 100%
  • Adequate function of other organ systems
  • Creatinine < 2.0 mg/dl and creatinine clearance > 50 cc/min/m2
  • Hepatic transaminases (ALT/AST) < 4 x normal, bilirubin < 2.0 mg/dl
  • Normal cardiac function by echocardiogram or radionuclide scan
  • Pulmonary function tests demonstrating FVC, CVC, and FEV1 of >60% of predicted for age. For adult patients DLCO > 60% of predicted. If patient cannot perform PFTs, clearance by the pediatric or adult pulmonologist will be required
  • No uncontrolled infections at the time of cytoreduction
  • NOT pregnant or lactating (must have a current negative pregnancy test)
  • HIV negative
  • Subject is not concurrently involved in any other clinical trial that affects engraftment or immune reconstitution (e.g. other hematopoietic growth factors).
  • Subject does not have any co-morbid condition, which in the view of the Principal Investigators, renders the patient at too high a risk from treatment complications and regimen related morbidity/mortality.

Sites / Locations

  • Duke University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Other

Other

Other

Other

Arm Label

20% primed UCB

20% un-primed

Double- 1 unit primed

Double- 1 unit unprimed

Arm Description

20% of UCB is ALDHbr sorted and primed and give on transplant day after conventional graft

20% of UCB is ALDHbr freshly sorted and give on transplant day 4-8 hrs after conventional graft

patient receives 1 conventional UCB unit and 1 unit that has been ALDHbr sorted and primed

Patient receives 1 UCB unit and a second UCB unit that has been freshly ALDHbr sorted

Outcomes

Primary Outcome Measures

To assess the safety of infusing ex vivo cytokine-primed ALDHbr cells isolated from banked unrelated umbilical cord blood (CB) into patients also receiving a standard unmanipulated unrelated CB transplant delivering >2.5x10e7 nucleated cells per kg.

Secondary Outcome Measures

To describe the biological effect of ex vivo cytokine-primed ALDHbr cells in these patients on neutrophil and platelet engraftment and immune reconstitution.
To describe the clinical outcomes in these patients: - incidence of infections -Non relapse mortality -incidence of acute and chronic graft-vs-host disease -overall survival at 180 days

Full Information

First Posted
June 3, 2008
Last Updated
June 27, 2017
Sponsor
Joanne Kurtzberg, MD
Collaborators
Aldagen
search

1. Study Identification

Unique Protocol Identification Number
NCT00692926
Brief Title
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
Official Title
A Pilot Trial of Unrelated Umbilical Cord Blood Transplantation Augmented With Ex Vivo CytokinePrimed ALDHbr Umbilical Cord Blood Cells
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
October 2005 (undefined)
Primary Completion Date
July 2012 (Actual)
Study Completion Date
July 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Joanne Kurtzberg, MD
Collaborators
Aldagen

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The main purpose of this investigational (not approved by the FDA) Phase I research is to test whether transplantation of umbilical cord blood cells can be safely supplemented with a transfusion of a portion of these cells that have been sorted (collected from a special machine called a cell sorter) and then either infused a few hours after the standard transplant or for some patients grown in a special system in the laboratory prior to the transplant, designed to increase the number of stem cells transplanted. This system is currently in the early phases of testing.
Detailed Description
The main purpose of this study is to test whether transplantation of umbilical cord blood cells can be safely supplemented with transfusion of a portion of these cells that have been grown in a special system (designed to increase the number of cells transplanted) in the laboratory prior to the transplant. This system is currently in the early phases of testing in a FDA-IND-sponsored clinical trial. If the patient consents to participate in this study, approximately 1/5th (20%) of the cord blood unit selected for the transplant will be treated per protocol. The first 3 patients will receive ALDHbr sorted cells but not primed in culture. This is to test the safety of the ALDHbr cells. The treated cells will be given to the patient on the day of transplant approximately 4 hours after the standard or conventional transplant which will be given from the 80% fraction of the cord blood unit. A total of 26 evaluable patients are to be enrolled as outlined below (protocol has been amended to allow this enrollment): 10 evaluable patients who received ALDHbr freshly sorted cells (20% portion) 10 evaluable patients who received ALDHbr sorted and cytokine primed cells (20% portion) 3 evaluable patients who received a conventional cord blood unit and a cord blood unit that has been ALDHbr sorted (sort of the UCB unit will be done on Day -1 due to the time it takes to actually perform the sort) 3 evaluable patients who received a conventional cord blood unit and a cord blood unit that has been ALDHbr sorted and cytokine primed (sort and priming will be done on day -5 as described later in the protocol)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
MDS, Anemia, Aplastic, Inborn Errors of Metabolism, Congenital Marrow Failure, Congenital Immunodeficiency Syndrome
Keywords
ALDHbr, Umbilical Cord Blood, Transplantation, Hematological malignancy, MDS, severe aplastic anemia, inborn error of metabolism, congenital marrow failure or congenital immunodeficiency syndrome, Hurler's Disease, Tay Sach's, PMD, Hunter's Syndrome, Krabbe, MLD, ALD, ALL, AML

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
37 (Actual)

8. Arms, Groups, and Interventions

Arm Title
20% primed UCB
Arm Type
Other
Arm Description
20% of UCB is ALDHbr sorted and primed and give on transplant day after conventional graft
Arm Title
20% un-primed
Arm Type
Other
Arm Description
20% of UCB is ALDHbr freshly sorted and give on transplant day 4-8 hrs after conventional graft
Arm Title
Double- 1 unit primed
Arm Type
Other
Arm Description
patient receives 1 conventional UCB unit and 1 unit that has been ALDHbr sorted and primed
Arm Title
Double- 1 unit unprimed
Arm Type
Other
Arm Description
Patient receives 1 UCB unit and a second UCB unit that has been freshly ALDHbr sorted
Intervention Type
Biological
Intervention Name(s)
ALDHbr Umbilical Cord Blood Cells
Intervention Description
ALDHbr sorted Umbilical Cord Blood Cells
Primary Outcome Measure Information:
Title
To assess the safety of infusing ex vivo cytokine-primed ALDHbr cells isolated from banked unrelated umbilical cord blood (CB) into patients also receiving a standard unmanipulated unrelated CB transplant delivering >2.5x10e7 nucleated cells per kg.
Time Frame
Prospective
Secondary Outcome Measure Information:
Title
To describe the biological effect of ex vivo cytokine-primed ALDHbr cells in these patients on neutrophil and platelet engraftment and immune reconstitution.
Time Frame
prospective
Title
To describe the clinical outcomes in these patients: - incidence of infections -Non relapse mortality -incidence of acute and chronic graft-vs-host disease -overall survival at 180 days
Time Frame
prospective

10. Eligibility

Sex
All
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: -Hematologic Malignancy: High risk ALL in first complete remission ALL or ANLL in second or subsequent remission ANLL in relapse MDS CML in any chronic phase or accelerated phase Severe aplastic anemia refractory to medical therapy The subject is negative for CNS disease at time of enrollment. Inborn errors of metabolism Hurler Syndrome (MPS I) Hurler-Scheie Syndrome Hunter Syndrome (MPS II) Sanfilippo Syndrome (MPS III) Morquio Syndrome (MPS IV) Maroteaux-Lamy Syndrome (MPS VI) Krabbe Disease (Globoid Leukodystrophy) Metachromatic Leukodystrophy (MLD) Adrenoleukodystrophy(ALD and AMN) Sandhoff Disease Tay Sachs Disease The subject does NOT have uncontrolled seizures, apnea, evidence of aspiration pneumonia or evidence of brain stem involvement on MRI scans Congenital marrow failure Amegakaryocytic thrombocytopenia TAR Kostmann's Syndrome Schwachman-Diamond Syndrome Blackfan-Diamond Anemia Congenital immunodeficiency syndromes requiring myeloablative therapy Wiscott Aldrich Syndrome LAD CGD FEL/HLH CVID/CID SUBJECT'S DONOR Subject does NOT have a 6/6 or 5/6 antigen matched related bone marrow donor. Suitably matched cord blood unit with adequate cell dose is available. Unit must be in a dual compartment bag. PERFORMANCE STATUS and ORGAN FUNCTION <55 years of age at time of enrollment. Lansky score between 60% and 100%, or a Karnofsky score between 50% and 100% Adequate function of other organ systems Creatinine < 2.0 mg/dl and creatinine clearance > 50 cc/min/m2 Hepatic transaminases (ALT/AST) < 4 x normal, bilirubin < 2.0 mg/dl Normal cardiac function by echocardiogram or radionuclide scan Pulmonary function tests demonstrating FVC, CVC, and FEV1 of >60% of predicted for age. For adult patients DLCO > 60% of predicted. If patient cannot perform PFTs, clearance by the pediatric or adult pulmonologist will be required No uncontrolled infections at the time of cytoreduction NOT pregnant or lactating (must have a current negative pregnancy test) HIV negative Subject is not concurrently involved in any other clinical trial that affects engraftment or immune reconstitution (e.g. other hematopoietic growth factors). Subject does not have any co-morbid condition, which in the view of the Principal Investigators, renders the patient at too high a risk from treatment complications and regimen related morbidity/mortality.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joanne Kurtzberg, MD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells

We'll reach out to this number within 24 hrs